Cadence's Acetavance gets priority review

The FDA has granted Cadence Pharmaceuticals priority review for its Acetavance NDA. Acetavance (intravenous acetaminophen) is being reviewed for the treatment of acute pain and fever in adults and children. The FDA has issued an action date for the NDA of November 13, 2009. Cadence release